DOYLESTOWN, Pa., Oct. 15 The Quigley Corporation (Nasdaq: QGLY), maker of the popular Cold-EEZE(R) zinc lozenges, http://www.coldeeze.com, is introducing new Kids-EEZE(R) Chest Relief, http://www.kids-eeze.com a single-ingredient, allopathic expectorant with guaifenesin to help children, ages six and up, suffering from uncomfortable chest congestion. Kids-EEZE(R) Chest Relief provides an alternative to the many multi-symptom children's cold products that could potentially lead to overmedication.
Advertisement
Kids-EEZE(R) Chest Relief is a unique, patented soft chew, available in great-tasting strawberry and grape flavors, that offers relief of chest congestion in a convenient dosage form for children six years of age and older.
Advertisement
"In recent years, the cough and cold remedy category has seen a growth in multi-symptom cold remedies, which has led to concerns about parents overmedicating their kids and treating symptoms their children weren't actually suffering from," says Albert Piechotta, executive director of communications and investor relations at the Quigley Corporation. "Kids-EEZE(R) Chest Relief, however, bucks the trend and helps simplify it for parents, since it has only one purpose and one ingredient - treating chest congestion with guaifenesin."
Guaifenesin is an expectorant that helps thin and loosen phlegm, or mucus, so that children can easily expel it from their lungs, relieving painful chest congestion and making coughs more productive.
"Chest congestion is a typical symptom of the common cold and one that is uncomfortable for children," says Paul Horowitz, M.D., F.A.A.P., of Discovery Pediatrics in Valencia, California. "Making a cough more productive can really make the child feel better and reduce the chances of that chest congestion turning into something more serious."
Each box of Kids-EEZE(R) Chest Relief contains 12, individually-wrapped, kid-friendly soft chews with 100 mg of guaifenesin. The convenience of a soft chew also ensures that children are getting the full
dosage of guaifenesin, without possible liquid spills, making it easier for parents to administer.
Kids-EEZE(R) Chest Relief is available nationwide at major retailers, including supermarkets, mass market retailers and chain and independent drug stores, as well as via online retailers, for a suggested price of $7.99.
For more information and cold and flu tips, visit http://www.kids-eeze.com.
About The Quigley Corporation:
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities and Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.
Forward-Looking Statements
Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.
Media Contact: Christina Occhipinti/Alyson O'Mahoney Robin Leedy & Associates 914-241-0086, ext. 14 [email protected] Investor Relations: Carl Hymans G.S. Schwartz & Co. 212-725-4500 [email protected]
SOURCE The Quigley Corporation
